STOCKS TELEGRAPH

Author: Maria Masood

  • Here’s the Reason of the Decline of BTCS, Inc. (BTCS) Stock in Premarket

    Here’s the Reason of the Decline of BTCS, Inc. (BTCS) Stock in Premarket

    BTCS, Inc. (BTCS) is a publicly-traded firm engaged in utilizing blockchain infrastructure and technology for various operations. An exclusive Staking-as-a-Service program is developed by the Company. The company is also going to develop an online asset data analysis platform for consumers to assess their crypto portfolios.

    The price of BTCS stock during the regular trading on January 13, 2022, was $6.88 with a significant incline of 2.69%. At last check in the premarket on January 14, 2022, the stock was down by 5.09%.

    BTCS: Events and Happenings

    On January 13, 2022, BTCS reported about the addition of Algorand to its infrastructural staking procedures. Asset development and smart contract execution were featured in ALGO’s blockchain. The company earned the revenue via the reward of additional tokens. On January 05, 2022, BTCS reported becoming the pioneer Bitcoin payable dividend company in Nasdaq. The Company refers it as a Bividend. It also gave futuristic insights into its projects.

    On November 15, 2021, BTCS reported that the Company acquired the status of the debt-free company. The company paid off a final batch of $1.0 million convertible notes which was issued in January 2021.

    BTCS: Key Financials

    On November 10, 2021, BTCS reported its financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows.

    Assets

    Total current assets of the company for Q3 2021 were $4.2 million.

    Revenue

    Total revenue collected for the third quarter of 2021 was $0.32 million.

    Net Loss per Share

    Basic and diluted net loss per share for Q3 2021 was $3.8 million or $0.59 per share. The net loss for the same period of 2020 was $1 million or $0.33 per share.

    BTCS: CEO Comments

    On November 02, 2021, BTCS reported the launch of its revised website. Speaking at the occasion, CEO of BTCS Charles Allen stated that the new website articulates the growth trajectory of the company for its stockholders. He further added that the management is executing the vision of integration of data analytics and SaaS program diligently.

    Conclusion

    BTCS stock is flying high these days as the company’s stock is notably 46% higher than the six months period. This incline is basically due to the company’s investor-centered strategic policies which are showing the results. The company’s stock declined in the current premarket session due to its announcement regarding the addition of Algorand to infrastructural operations. In short, the company’s stock is in good shape to attract the stockholder’s interest.

  • Here’s why Ocugen, Inc. (OCGN) Stock Leaped Forward in Premarket Session

    Here’s why Ocugen, Inc. (OCGN) Stock Leaped Forward in Premarket Session

    Ocugen, Inc. (OCGN) is a leading innovative clinical-stage biopharmaceutical company. It is primarily focused on the discovery, development, and commercialization of treatments for multiple retinal diseases or blindness and is also under the process of vaccine development for COVID-19 patients. Some of the lead product candidates of the company include OCU400, OCU410, OCU200, and COVAXIN.

    The price of OCGN stock during the regular trading on December 30, 2021, was $4.83 with a significant increase of 10.27%. At last check in the premarket on December 31, 2021, the stock was further up by 1.04%.

    OCGN: Events and Happenings

    On December 30, 2021, OCGN reported that its collaborator Bharat Biotech reported the outcomes of clinical trials of COVID vaccine COVAXIN. The study was executed on children of 2 – 18 years age. The outcomes represented a vigorous counterbalancing antibody response and a promising safe profile on the pre-print server medRXiv. The vaccine was administered in two doses 28-days apart from each other. The outcomes depicted more than a 93% drop in severe conditions. The company had already submitted its application for the status of Emergency Use Authorization on November 5.

    OCGN: CEO Comments

    On this auspicious occasion, Shankar Musunuri, CEO of OCGN said that the above-mentioned data is the first positive vaccine data in children. He further added that the outcomes represented that the vaccine administered in two-doses delivered a robust immune response in children.

    On December 20, 2021, OCGN reported that the compensation committee of BoD approved to acquire a sum of 6,750 shares. The shares belong to its common stock and restricted stock units and cover a sum of 1,150 shares of common stock. The stock options and RSUs were granted as of December 16, in accordance with Nasdaq Listing Rule 5635(c)(4).

    On December 15, 2021, OCGN reported that data studying immune response was published on the preprint server medRvix. The data was taken after two doses of COVAXIN, from a third-party trial. The study confirmed that the vaccine showed a sharp immune memory versus the spike and nucleoproteins of the virus.

    OCGN: Key Financials

    On November 9, 2021, OCGN reported third-quarter 2021 financial results that ended September 30, 2021. Some of the key updates are mentioned below

    Net Loss per Share

    Basic and diluted net loss per share was reported to be $10.7 million or $0.05 per share for Q3 2021 as compared to $10.4 million or $0.07 per share for the same period the prior year.

    Assets

    The total assets of the company reported for Q3 2021 were $113 million as compared to the same period of 2020 when the assets were $19 million.

    Conclusion

    OCGN reported a 23% decline in the stock price as compared to the past month. The current market conditions are favoring the company’s stock as the price of the stock surged in the premarket. The incline was basically the outcome of positive results of the vaccine data in children. The analysts are expecting the company’s stock to skyrocket further in the coming days as a result of this announcement.

  • SuperCom Ltd. (SPCB) Stock Dipped in Premarket Session, Here’s the Reason

    SuperCom Ltd. (SPCB) Stock Dipped in Premarket Session, Here’s the Reason

    SuperCom Ltd. (SPCB) is a leading international conventional and digital identity solutions provider. The company also provides extra security and identification to governments and businesses. MAGNA is a platform for e-passport issuance, biometric visa issuance, digital driving licenses, and election management. Another important program of the company is the PureRF platform which helps in identification, tracking and monitoring the people and objects.

    The price of SPCB stock during regular trading on December 30, 2021, was $0.61 with a tremendous gain of 40.10%. At last check in the pre-market, the stock declined by 3.44%.

    SPCB: Events and Happenings

    On December 30, 2021, SPCB reported about a notification by the chairman of the board about the recent acquisition of the company’s 512,000 shares in the open market. The process occurred under the purchase procedure to acquire approximately 3 million SPCB shares in the Open Market.

    On December 20, 2021, SPCB reported that Safend had been designated by a security agency and cyber security businesses to expand their security protocols. Safend is SPCB’s cyber security sub-division. The company is expected to receive more than $0.35 million from these ventures.

    On December 17, 2021, SPCB reported about the receipt of a letter from Nasdaq, about non-compliance with Nasdaq Listing Rule 5550(a)(2). The Company’s closing bid price for the stock was less than $1.00 per share. On December 2 and 9, 2021, SPCB reported about signing a contract related to electronic monitoring in Texas and Idaho respectively.

    SPCB: CEO Comments

    Ordan Trabelsi, CEO of the company stated that the novelties for house arrest and GPS offender monitoring had given innovative capacities to the marketplace. He further added that the main focus of the company is public safety using cell tower location, Wi-Fi location, and RF tethering.

    SPCB: Key Financials

    On November 11, 2021, SPCB announced the key financial highlights for three months ended September 30, 2021.

    Revenue and Assets

    Revenue reported for Q3 2021 was $3.1 million as compared to the same period prior year when it was $2.4 million. The total current assets of the company for the third quarter of 2021 were $31.4 million.

    Net Loss

    Net loss for the third quarter of 2021 was $2.4 million as compared to the same period of 2020 when it was $3.7 million. The net loss decreased over the period of the year.

    On October 7, 2021, SPCB reported about the receipt of a project award by one of its subsidiaries. The project will provide rehabilitation services. One of the main emphasis of the project was creating employment services for women.

    Conclusion

    SPCB stock showed a slight decline (11%) during the past month, yet the company recovered its stock price tremendously. But the current aftermarket dip is possibly the result of the announcement by the company’s chairman about the acquisition of shares. The analysts are optimistic that the company will play its part to lift the stock price. It will in turn attract the consumers in the coming days.

  • WISekey International Holding AG (WKEY) Stock Rise in Premarket. Here’s why

    WISekey International Holding AG (WKEY) Stock Rise in Premarket. Here’s why

    WISekey International Holding AG (WKEY) is one of the leading international cybersecurity company. The company functions through two portions Internet of Things (IoT) and mPKI. Company’s microprocessors protect the pervasive computing influencing the current IoT. The cryptographic Root of Trust (RoT) operates protected verification and identification, in virtual and physical environments for IoT, Blockchain, and AI. The company also provides ISTANA services for managing the components in AI-based cars by providing PKI-based digital identity.

    The price of WKEY stock during the regular trading on December 29, 2020, was $4.01 with a decline of 1.23%. At last check in the premarket on December 30, 2021, the stock jumped by 5.24%.

    WKEY: Events and Happenings

    On December 29, 2021, WKEY reported about the presentation of a summary of the company’s important milestones achieved in 2021. Company’s executives discussed recent business developments, financial indicators, prospects for the year 2021, and developmental prospects for 2022.

    On December 23, 2021, WKEY reported about the support of the EU recent Data and Cloud Coalition. The coalition offered a faster step toward digital independence. It will result in reduced dependency on foreign tech providers. As a solid footstep towards this support, the company previously operated a Swiss-EU-created WISeID Cloud Storage program.

    On December 22, 2021, WKEY, FOSSA Systems, and the City Council of La Línea de la Concepción co-announced the completion of the first ground station. The station served as the regulator base for the trajectory of IoT satellites. Earlier this year an MoU was signed between the parties for the making of a 4th Industrial Revolution Center of Excellence.

    On December 20, 2021, WKEY reported about the induction of new artists for the WISe.ART NFT Marketplace. WISe.ART NFT perceive a future for the indications that upsets the content creation economics and impact on the internet.  On December 13, 2021, WKEY reported about the celebration of the 15th anniversary of its collaboration with CISCO. The company recently delivered the hundredth million chip to CISCO. The company also added a second industrial supply to support the business development.

    Conference Presentations

    On December 9, 2021, WKEY reported about the presentation of the latest developments in blockchain identity and WISe.ART NFT using CasperLabs. The presentation was held on December 13. On December 8, 2021, WKEY reported that the company executives presented at the Imperial Capital Security Investor Conference. The conference held on December 15. On December 6, 2021, WKEY reported that the company’s WISe.ART Marketplace was between the NFT displays at the International Art Week.

    On December 1, 2021, WKEY reported about its partnership with OISTE.ORG Foundation. Both organizations co-presented entitled Digital Human Rights to Privacy and Digital Identity at World Law Congress. On November 30, 2021, WKEY reported to hold a metaverse holograminar at its Investor Day on December 13

    Conclusion

    WKEY stock fell 44% from the past six months, so the recent incline is the fresh air breath for the investors. The recent premarket rise is likely the outcome of taking the investors into confidence. Also, the company provided a summary of the achieved milestones of 2021. Analysts are suggesting it as a good move.

  • Flotek Industries, Inc. (FTK) Stock Rising in Aftermarket. Here’s why.

    Flotek Industries, Inc. (FTK) Stock Rising in Aftermarket. Here’s why.

    Flotek Industries, Inc. (FTK) is an innovative leading technology-driven, green chemistry tech and data analytics company. It decreases the environmental impact of energy on different components of the ecosystem. The company operates in two segments. The Chemistry portion develops high-quality disinfecting and cleaning products for consumer use. The data segment provides its consumers with real-time data about different products.

    The price of FTK stock during the regular trading on December 27, 2021, was $0.56 with a significant decline of 8.59%. At last check in the aftermarket the stock was tremendously surged by 49.29%.

    FTK: Events and Happenings

    On December 27, 2021, FTK had received an unsolicited show of interest for a possible deal of the Company wholly or partly. Company’s top management had involved Piper Sandler & Co. as a financial advisor to sort out with the assessing process.

    On December 10, 2021, FTK reported about receipt of notice from the New York Stock Exchange. The notice states that the average closing price of the FTK’s shares of common stock was less than $1.00 per share. The price was lower than the obligation for listing on the NYSE.

    On November 29, 2021, FTK reported that the top management of the company represented in Virtual Noble Capital Markets’ Road Show Series. The event was held on December 1, 2021.

    FTK: Key Financials

    On November 8, 2021, FTK reported its third quarter results for the three months ended September 30, 2021. Some of the main highlights are as follows

    Revenue

    Revenue generated by the company for third quarter 2021 was $10.2 million as compared to $12.7 million for the third quarter 2020. The revenue decreased 20.1% from last year.

    Net Income/Loss per Share

    Net income per basic and diluted share for the third quarter 2021 was $0.5 million or $0.01 per share, as compared to a net loss of $45.2 million, or $0.66 per share for the same quarter of 2020.

    Total Current Assets

    Total current assets reported for Q3 2021 were $46.3 million.

    FTK: CEO Comments

    John W. Gibson, CEO of FTK told that revenues for the third quarter surged as compared to the previous quarter. He further added that the customer growth also improved by 22% sequentially.

    On October 27, 2021, FTK’s subsidiary reported about ATEX/IECEx certified online analyzers. The Verax ISX/IMX™ analyzers can withstand poor environmental conditions. They can also provide real-time data regarding different aspects. On October 15, 2021, FTK reported about Automated Interface Detection Algorithm (AIDA), a near infrared real-time analyzer. It provides real-time exposure of interfaces in liquid pipeline.

    Conclusion

    FTK stock is on a declining trend from the past week as 28% reduction was observed. But the aftermarket showed promising results for the investors and stockholders. The major leap in aftermarket is possibly due to company’s announcement of receipt of interest. The analysts are optimistic about the company that it will regain its lost momentum.

  • Tracon Pharmaceuticals, Inc. (TCON) Stock Dipped in Regular Trading, Here’s What you Should Know

    Tracon Pharmaceuticals, Inc. (TCON) is a leading clinical stage company engaged in the development and commercialization of oncology related therapies. The company also develops treatment for macular degeneration and fibrotic diseases. The lead product candidates is Envafolimab, an antibody injected subcutaneously for treatment of ENVASARC trial for sarcoma. TRC102 is another product in Phase 2 trial for the treatment of lung cancer. TJ004309 is in Phase 1 clinical trials for the treatment of progressive solid tumors.

    The price of TCON stock, at last check during the regular trading on December 27, 2021, was $3.00. the showed a notable decline of 13.86%.

    TCON: Events and Happenings

    On December 27, 2021, TCON reported that the Independent Data Monitoring Committee recommended continued accretion in both the units of envafolimab. Toleration level of Envafolimab was good, with only a minor adversity reported in some patients. On November 29, 2021, TCON announced that its collaborators Alphamab Oncology and 3D Medicines reported that envafolimab received marketing certification from the Chinese Administration.

    On November 11, 2021, TCON reported that the top management of the company presented at the Virtual Jefferies London Healthcare Conference. The conference held on November 18-19, 2021.

    TCON: Key Financials

    On November 03, 2021, TCON reported financial results for the third quarter ended September 30, 2021. Some of the key updates are as follows

    Net loss per Share

    Basic and diluted net loss for the third quarter of 2021 was $7.0 million or $0.38 per share, as compared to $4.0 million or $0.38 for the same quarter of 2020.

    Total Current Assets

    Total current assets reported by the company for Q3 2021 were $31.1 million as compared to the same period prior year when they were $27.4 million.

    On October 11, 2021, TCON and Eucure Biopharma entered into a partnership for the research and development of YH001. It is used in treatment of soft tissue sarcoma. On September 13, 2021, TCON reported that the top management of the company presented at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit. The summit held on September 20, 2021.

    On September 07, 2021, reported that the top management of the company presented at the H.C. Wainwright 23rd Annual Global Investment Conference. It held on September 13-15, 2021. On September 02, 2021, TCON reported that the top management of the company presented at the Wells Fargo Healthcare Conference. The conference virtually held on September 9, 2021.

    Conclusion

    The price of TCON stock s 15% up in comparison to the past month but it remarkably declined in the regular trading. The decline is the result of uncertain market environment. Earlier the company reported positive outcomes from IDMC for Envasarc trials. The analysts believe the company’s strategies are strong to attract potential investment in the future.

  • BiondVax Pharmaceuticals Ltd. (BVXV) Stock Dipped in Premarket, Here’s why

    BiondVax Pharmaceuticals Ltd. (BVXV) is a leading pharmaceutical company. It primarily focuses on the development, manufacture and commercialization of novel treatments for prevention of different infectious diseases. One of the leading product candidates of the company is a novel nano sized antibody (NanoAb). Other pipeline products are also in the process of development.

    The price of BVXV stock during the regular trading on December 23, 2021, with a 4.79% drop was $2.78. At last check in the pre market on December 27, 2021, the stock further dropped by 17.63%.

    BVXV: Events and Happenings

    On December 27, 2021, BVXV reported the pricing of underwritten public offering of 3,813,560 shares at a price of $2.36 per share. The gross proceeds reported to the company were $9.0 million. Each share presents 40 ordinary shares of the company.

    On December 22, 2021, BVXV reported about the collaboration with Max Planck Society and the University Medical Center Göttingen, for the development and marketing of novel COVID-19 NanoAbs. Under the broader agreement, NanoAbs could be used for other disease symptoms in the near future. This aspect of NanoAbs reinforce its unique characteristics of binding affinity, high temperature stability and more efficient pathways of administration.

    BVXV: Key Financials

    On November 30, 2021, BVXV reported its financial results for third quarter ended September 30, 2021. Some of the key highlights are as follows

    Total Assets

    The total assets reported by the company for Q3 2021 were $7.9 million as compared to the same period of 2020 when the assets were $11 million.

    Net Income/Loss per Share

    Basic and diluted net loss per share for Q3 2021 was $2.8 million or $0.02 per share against the same period of 2020 when net income was $17.6 million and per basic share it was $0.12 while per diluted share it was $0.10.

    On November 15, 2021, BVXV reported that the top management of the company presented at the 7th Virtual H.C. Wainwright Annual Conference on the same date. On October 19, 2021, BVXV reported about the 5-year strategic research collaboration with the Max Planck Society and the University Medical Center. The contract is determined by the accomplishment of definitive agreements.

    Conclusion

    The BVXV stock showed significant hike i.e., 51% in comparison to the past month. In the premarket session the stock price dropped sharply possibly due to the company’s announcement of $9 million pricing of underwritten offering of shares. The earlier progress shown by the company is reciprocated and the company should think about new policies to attract the investment.

  • Here’s why RISE Education Cayman Ltd (REDU) Stock Skyrocketing in the Premarket

    Rise Education Cayman Ltd (REDU) is an innovative junior English language training provider. Some of the educational programs by the company include the sale of course material, study tours, and a variety of educational courses. The company also provides consultation services regarding tests and admissions. The company also offers STEAM courses enrollment that includes integration of various subjects such as science, technology, engineering, arts, and math.

    The price of REDU stock during the regular trading on December 23, 2021, was $0.53 with a significant increase of 5.04%. At last check in the premarket on December 27, 2021, the stock was remarkably up by 14.45%.

    REDU: Events and Happenings

    On December 23, 2021, REDU reported the outcomes of the Company’s extraordinary general meeting of shareholders held on the same date. Shareholders at the meeting, via a resolution, approved various matters of interest.

    On December 1, 2021, REDU reported that Wuhan Xinsili Culture Development company, Rise Education Information Consulting company, Beijing Step Ahead Education Technology Development company, RISE Education International company and Rise IP Limited company had partnered for a purchase agreement.

    On November 22, 2021, REDU reported about the resignation of Ernst & Young Hua Ming LLP. It was independent registered public accounting firm of REDU. The decision was effective from November 19, 2021. On October 27, 2021, REDU reported about the receipt of an initial proposal letter on October 18, from the company’s CEO. The letter was forwarded with regards to substantially purchase all the assets of Rise Education Information Consultation Company, and Beijing Step Ahead Education Technology Development Company.

    On October 8, 2021, REDU reported the receipt of letter from Nasdaq. The letter indicated that REDU was not complying with the least bid price obligation of US$1.00 per share.

    On August 16, 2021, REDU updated that the company had not published the quarterly earnings report. The company will inform soon about its recent earnings report.

    Conclusion

    The REDU stock is 10% down from the past month. The company is remarkable in its premarket performance and reported 15% surge in the stock price mainly due to the success of its general meeting of stockholders. It points out the successful strategies of the company which attracted the potential investors.

  • The Southern Company (SO) Stock Dropped in the Aftermarket Despite any Clear Reason.

    Southern Company (SO) is a leading company which is engaged in electricity distribution as well as natural gas distributor. The company also provides fiber optics network and the communication services to the customers. The company also owns power generation assets. The company believes in clean and carbon-free energy production.

    The price of SO stock during the regular trading on December 23, 2021 was $66.54 with a little decline of 0.17%. At last check in the aftermarket, the stock price further declined by 7.6%.

    SO: Events and Happenings

    On December 24, 2021, a subsidiary of SO and Microsoft co-announced about their latest venture, a $0.2 million investment in Clark Atlanta University. Via this platform, the students will build an innovative solar powered generation platform. The generator will serve the purpose of back-up energy source for the university campus. On December 21, 2021, a subsidiary of SO informed about the grant given to United Negro College Fund to support HBCUs across the state. The grant was given in order to provide under-represented students the equal opportunity to college education.

    On December 7, 2021, a subsidiary of SO and Mercedes Benz got a nod from the Alabama Public Service Commission regarding the anticipated 80-megawatt Solar Power Project. On November 30, 2021, a subsidiary of SO and Georgia Aquarium co-announced about adding a new element in southern sea otter display. The novel technology included two interesting games. One which exhibited the role of southern sea otter in minimizing carbon emission and the other one in making the utilization of natural gas carbon neutral.

    On November 24, 2021, SO reported about the start of operational facilities of 118-megawatt Glass Sands Wind Facility in Oklahoma. On November 18, 2021, SO and the U.S. Department of Energy have joined hands for the world’s foremost critical fast-spectrum salt reactor. The partnership will be first of its kind of Molten Chloride Reactor Experiment.

    On November 12, 2021, SO and Energy Impact Partners co-announced about the launch of company’s Flagship Fund. The Fund received $1 billion for the acceleration of the global decarbonization protocol. On November 8, 2021, a subsidiary of SO announced to release its Request for Proposals (RFP) for 1,030 MW of renewable energy sources for 2023 and 2024.

    SO: Key Financials

    On November 4, 2021, SO announced its third-quarter 2021 financials for three months ended September 30, 2021. Some of the key updates are as follows

    Net Income

    Net income reported by the company for Q3 2021 was $1.1 billion as compared to $1.25 billion for the same quarter of 2020.  The basic earnings per share for Q3 2021 were $1.04 per share versus $1.18 per for same period prior year.

    Conclusion

    SO stock is 5% up from the past month but on a declining verge in the aftermarket. Although the current market conditions suit the company in terms of different pipeline collaborations but its stock dropped due to uncertain market conditions. The analysts are confident that the stock will regain its lost momentum rapidly.

  • electroCore, Inc. (ECOR) Stock Surged in After Market. Here’s What you Should Know

    electroCore, Inc. (ECOR) is a leading innovative development and commercialization bioelectronic medicine company. The company primarily focuses on the treatment of different neurological conditions through its non-invasive vagus nerve stimulation therapy (nVNS). The company specializes in making therapies for patients with migraine, episodic cluster headaches, and hemicrania.

    The price of ECOR stock during the regular trading on December 23, 2021, was $0.69 with an incline of 3.81%. At last check in the aftermarket, the stock was further significantly up by 6.47%.

    ECOR: Event and Happenings

    On December 16, 2021, ECOR reported about its collaboration with different global and well-known distribution partners for giving the exclusive distribution rights of gammaCore Sapphiren nVNS in Cyprus and the Gulf States. On December 15, 2021, ECOR unveiled an e-commerce webshop for patients. People who wanted to purchase a gammaCore Sapphire nVNS device were required to fill a healthcare questionnaire.

    On December 14, 2021, ECOR reported about the clinical trials to evaluate the potential of gammaCore nVNS for the treatment of Post Traumatic Stress Disorder. The patients reported significant improvement in their overall condition. On December 13, 2021, ECOR reported that the United States Patent and Trademark Office had issued Patent No. 11,191,953 to ECOR. The number was issued in relation to the treatment of acute stroke symptoms or transient ischemic attack.

    On November 11, 2021, ECOR reported that the top officials of the company presented at the Virtual Canaccord Genuity MedTech & Diagnostics Forum on November 18, 2021.

    ECOR: Key Financials

    On November 04, 2021, ECOR reported third-quarter 2021 financial results that ended September 30, 2021. Some of the highlights are as follows

    Revenue

    Revenue of $1.5 million was reported for Q3 2021 representing an increase of 38% from the same period of 2020.

    Net Loss per Share

    Basic and diluted net loss per share for Q3 2021 was $3.9 million or $0.06 per share as compared to the same period of 2020 when it was $4.18 million or $0.10 per share.

    Total Assets

    The total assets of ECOR for Q3 2021 were reported to be $47.5 million.

    On October 20, 2021, ECOR reported the research published in the British Journal of Healthcare Management. The title of the paper was “nVNS for treatment of cluster headache: a retrospective review of prescribing in England,”. On October 14, 2021, ECOR reported that it received a revised Medical Device License from Canadian Health Department to expand the label of gammaCore nVNS in adolescents.

    On September 30, 2021, ECOR reported that the top management of the company presented at the Cantor Fitzgerald Virtual Global Healthcare Conference held on September 30, 2021.

    Conclusion

    Although ECOR stock declined 6% from the past month. But the recent surge in the stock price which is mainly the result of uncertain market conditions has proven beneficial for the company’s stockholders. Analysts are suggesting that the company has the potential to attract potential investments.